NEW DELHI, June 22 (Xinhua) - Sameeyaha tallaalka Hindiya ee Bharat Biotech's Covaxin ayaa muujiyay waxtarka boqolkiiba 77.8 ee tijaabooyinka wejiga III, warbaahinta maxalliga ah ayaa sheegay Talaadadii.
"Bharat Biotech's Covaxin waa 77.8 boqolkiiba wax ku ool ah ka ilaalinta COVID-19, marka loo eego xogta laga soo xigtay tijaabooyinka wejiga III ee lagu sameeyay 25,800 kaqeybgalayaasha India oo dhan," warbixin ayaa lagu yiri.
Heerka wax-ku-oolnimada ayaa soo baxay Talaadadii ka dib markii Guddiga Khabiirka Maaddada ee Maaddada Guud ee Hindiya (DCGI) ay kulmeen kana wada hadleen natiijooyinka.
Shirkadda dawooyinka ayaa u soo gudbisay xogta tijaabada wajiga III ee tallaalka DCGI dhammaadka usbuuca.
Warbixinadu waxay sheegeen in shirkadu la filayo inay qabato kulan "horu-gudbin" ah oo ay la yeelato masuuliyiinta Ururka Caafimaadka Adduunka Arbacada, si looga wada hadlo tilmaamaha soo gudbinta kama dambaysta ah ee xogta iyo dukumentiyada loo baahan yahay.
Hindiya waxay bilawday tallaalka ballaaran ee ka dhanka ah COVID-19 Jan. 16 iyadoo bixisay laba tallaal oo Hindiya lagu sameeyay, oo kala ah Covishield iyo Covaxin.
Machadka Serum ee Hindiya (SII) ayaa soo saaraya AstraZeneca-Oxford University's Covichield, halka Bharat Biotech ay iskaashi la samaysay Golaha Hindida ee Cilmi-baarista Caafimaadka (ICMR) ee soo saarista Covaxin.
Tallaalka Sputnik V ee Ruushku sameeyay ayaa sidoo kale laga sameeyay dalka.Enditem
Waqtiga boostada: Juun-25-2021